Production (Stage)
Bone Biologics Corporation
BBLG
$4.89
-$0.05-1.01%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 614.90K | 450.40K | 521.30K | 459.20K | 657.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.04M | 1.55M | 951.00K | 809.70K | 903.50K |
| Operating Income | -1.04M | -1.55M | -951.00K | -809.70K | -903.50K |
| Income Before Tax | -1.02M | -1.52M | -941.00K | -783.70K | -866.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.02M | -1.52M | -941.00K | -783.70K | -866.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.02M | -1.52M | -941.00K | -783.70K | -866.00K |
| EBIT | -1.04M | -1.55M | -951.00K | -809.70K | -903.50K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.92 | -3.68 | -14.21 | -4.02 | -7.86 |
| Normalized Basic EPS | -1.20 | -2.30 | -2.01 | -2.52 | -4.91 |
| EPS Diluted | -1.92 | -3.68 | -14.21 | -4.02 | -7.86 |
| Normalized Diluted EPS | -1.20 | -2.30 | -2.01 | -2.52 | -4.91 |
| Average Basic Shares Outstanding | 530.50K | 413.30K | 292.20K | 194.70K | 110.20K |
| Average Diluted Shares Outstanding | 530.50K | 413.30K | 292.20K | 194.70K | 110.20K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |